BeiGene PD-1 Tislelizumab Shows Survival Benefit In Esophageal Cancer

 
• By Jessica Merrill
  
Esophageal Cancer vector
BeiGene's PD-1 inhibitor improved overall survival in esophageal cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category